Angiogenesis inhibitors for the treatment of epithelial ovarian cancer-Reference-Cited by-同舟云学术

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer

Published:2023-04-18 Issue:4 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Gaitskell Kezia¹,Rogozińska Ewelina²,Platt Sarah³⁴,Chen Yifan⁵,Abd El Aziz Mohamed⁶,Tattersall Abigail⁷,Morrison Jo⁸

Affiliation:

1. Cancer Epidemiology Unit, Nuffield Department of Population Health; University of Oxford; Oxford UK

2. The Evidence-Based Medicine Consultancy Ltd; Bath UK

3. Obstetrics and Gynaecology; St Mary's Hospital, University Hospitals Bristol and Weston NHS Foundation Trust; Bristol UK

4. Department of Gynaecological Oncology; St. Michael's Hospital; Bristol UK

5. Oxford Medical School; University of Oxford; Oxford UK

6. Internal Medicine Department; Mercyone North Iowa; Mason City Iowa USA

7. Kingston Hospital NHS Foundation Trust; Kingston upon Thames UK

8. Department of Gynaecological Oncology; Musgrove Park Hospital, Somerset NHS Foundation Trust; Taunton UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference399 articles.

1. Du Bois A Kristensen G Ray-Coquard I Reus A Pignata S Colombo N AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/-nintedanib for advanced ovarian cancer International Journal of Gynecological Cancer 2013 7 8

2. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer;Harter;Oncology Research and Treatment,2014

3. Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC);Kristensen;Journal of Clinical Oncology,2014

4. LUME-Ovar 1: BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer www.clinicaltrials.gov/ct2/show/NCT01015118

5. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer;Ray-Coquard;International Journal of Cancer,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

2. Current Evidence on Molecular Mechanisms of Andrographolide in Cancer;Current Medicinal Chemistry;2024-06-11

3. Exosomal noncoding RNAs in gynecological cancers: implications for therapy resistance and biomarkers;Frontiers in Oncology;2024-04-26

4. Drug repurposing for cancer therapy;Signal Transduction and Targeted Therapy;2024-04-19

5. Endothelial β-catenin upregulation and Y142 phosphorylation drive diabetic angiogenesis via upregulating KDR/HDAC9;Cell Communication and Signaling;2024-03-15